CYP19A1 and cancer: For instance, Huiart and colleagues found that, among 233 patients with cancer who were receiving aromatase inhibitors (AIs), the hazard ratio of discontinuing AIs was 3.2 times greater among subjects using CAM compared to subjects who did not (95% CI: 1.5–6.9).